Related Experiment Video
Updated: Apr 7, 2026
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Repurposing Diclofenac as an Anticancer Agent: Suppression of Breast Cancer and Progression through EPAS1-EFNA1
Wenhui Zhang1, Qingsong Huang1,2, Lijiao Zheng1
1Henan Key Laboratory of Immunology and Targeted Drugs, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, 453003, P.R. China.
Introduction:
Breast cancer, the most common female malignant tumor, endangers women's health. Traditional anticancer drugs often lead to resistance, so new therapeutics are urgently needed. This study explored the anti-tumor mechanism of diclofenac in breast cancer.
Methods:
Diclofenac's effects on breast cancer cell proliferation, migration, invasion, and apoptosis were assessed via in vitro (MTT, Colony formation, Transwell, Wound healing, Flow cytometry, Immunofluorescence) and in vivo (Xenograft model) assays. RNA-seq identified diclofenac's target. EFNA1 expression was analyzed by RNA-seq, qRT-PCR, and Western blot. The luciferase assay investigated diclofenac-mediated EFNA1 transcriptional regulation; overexpression strategies validated EFNA1's involvement in mediating diclofenac's anticancer activities.
Results:
Diclofenac inhibited proliferation, migration, and invasion, and induced apoptosis in T47D and MDA-MB-231 cells, and suppressed xenograft growth. It reduced EFNA1 expression by impairing EPAS1 binding to the EFNA1 promoter's -1353~-782 region; EFNA1 overexpression abrogated diclofenac's anti-tumor effects, confirming EFNA1 as a critical mediator of diclofenac's effects.
Discussion:
Our findings reveal that diclofenac exerts anti-breast cancer effects by targeting EFNA1 via EPAS1-mediated transcriptional regulation. It not only provides novel insights into the COX-independent anticancer mechanism of diclofenac but also highlights EFNA1 as a potential therapeutic target for breast cancer, although further in vivo validation and larger-cohort studies are warranted.
Conclusion:
Diclofenac inhibits breast cancer progression by down-regulating EFNA1 through impairing EPAS1 binding to its promoter. These findings support repurposing diclofenac into an established and readily accessible medication as a promising and cost-effective agent for breast cancer treatment, while also underscoring EFNA1's potential role in guiding treatment stratification.
Insights
Diclofenac shows promise in treating breast cancer by inhibiting tumor growth and spread. It works by reducing EFNA1 expression, offering a new therapeutic strategy for this common cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Breast cancer is a leading cause of mortality in women, with drug resistance necessitating novel therapeutic approaches.
- Exploring non-steroidal anti-inflammatory drugs (NSAIDs) like diclofenac for anticancer properties is crucial.
Purpose of the Study:
- To elucidate the anti-tumor mechanisms of diclofenac in breast cancer.
- To identify diclofenac's molecular targets and pathways involved in its anticancer effects.
Main Methods:
- In vitro assays (MTT, colony formation, Transwell, wound healing, flow cytometry) and in vivo xenograft models assessed diclofenac's efficacy.
- RNA sequencing (RNA-seq) identified EFNA1 as a key target, with expression validated by qRT-PCR and Western blot.
- Luciferase assays and overexpression studies confirmed EPAS1-mediated transcriptional regulation of EFNA1 by diclofenac.
Main Results:
- Diclofenac significantly inhibited breast cancer cell proliferation, migration, invasion, and induced apoptosis.
- In vivo studies demonstrated diclofenac's suppression of tumor growth in a xenograft model.
- Diclofenac reduced EFNA1 expression by disrupting EPAS1 binding to the EFNA1 promoter; EFNA1 knockdown reversed diclofenac's anti-cancer effects.
Conclusions:
- Diclofenac exerts anti-breast cancer effects by down-regulating EFNA1 through EPAS1-mediated transcriptional regulation.
- This study reveals a COX-independent anticancer mechanism for diclofenac and highlights EFNA1 as a potential therapeutic target.
- Repurposing diclofenac offers a cost-effective strategy for breast cancer treatment, with EFNA1 potentially guiding treatment stratification.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...